Article
Six-month results show 88% achieving 20/40 for distance, 70% achieving J3 or better
Study reveals temperature fluctuations at home may compromise anti-VEGF drug safety
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Sling Therapeutics announces topline efficacy and safety data from Phase 2b/3 LIDS trial on linsitinib
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Glaukos announces several positive clinical updates for its iDose platform
Rayner launches redesign of IOL calculator RayTrace